Human Papillomavirus and Cytomegalovirus Therapeutics Market on the Rise Owing to Alarming Transmission of DNA Viruses among Global Population
Human Papillomavirus (By Drug Class and Applications) and Cytomegalovirus (By Drug Type and Applications) Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 – 2020
Rising incidence of human papillomavirus (HPV) infections in developing as well as underdeveloped economies and increased seroprevalence have respectively driven the global human papillomavirus and cytomegalovirus therapeutics market over recent years, states a recently published report by Transparency Market Research. The report is titled “Human Papillomavirus and Cytomegalovirus Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020” and is available for sale on the company website.According to the research report, the global HPV therapeutics market was worth US$1.40 billion in 2013 and is projected to be worth US$2.34 billion in 2020, growing at a 7.7% CAGR during the report’s forecast period of 2014 to 2020. The CMV therapeutics market, on the other hand, stands to grow from US$0.87 billion in 2013 to US$0.92 billion in 2020 at a meager CAGR of 1.5% between 2014 and 2020.
The HPV therapeutics market is segmented on the basis of drug class, application, and pipeline drugs. In terms of revenue, immunomodulators were the dominant drug class in 2013 owing to cost-effectiveness, increased efficiency, and its nature as a non-invasive treatment. Application-wise, the segment of genital warts held the largest share of the HPV therapeutics market that year.Application, antiviral drugs, and pipeline drugs are the criteria based on which the CMV therapeutics market is segmented. Among the major antiviral drugs, ganciclovir and valganciclovir held the largest share of the CMV therapeutics market in 2013, while retinitis was the...